Approved & therapeutic
VIP
Vasoactive Intestinal Peptide
A neuropeptide found throughout the body that regulates blood flow, immune responses, and gut function. Studied for its role in chronic inflammatory conditions.
Also known as: Aviptadil
- Status
- VIP is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- ~1-2 minutes (rapid degradation)
- How it's taken
- Intranasal spray or subcutaneous injection
- Mechanism
- Other
How VIP works
Acts on VPAC1 and VPAC2 receptors to dilate blood vessels, reduce inflammation, and regulate immune cell activity. In the gut, it controls secretion and motility.
What research has looked at
- Powerful anti-inflammatory
- May help with chronic inflammatory response syndrome (CIRS)
- Supports healthy gut motility
- Bronchodilator effects
- Neuroprotective properties
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Diarrhea
- Low blood pressure
- Flushing
- Rapid heart rate
- Nasal congestion (intranasal use)
- Not widely available
Sources
- PubMed research on vasoactive intestinal peptide VIP · NIH · National Library of Medicine
- StatPearls / NCBI Bookshelf on vasoactive intestinal peptide · NCBI Bookshelf
- DrugBank record for vasoactive intestinal peptide · DrugBank
Track VIP in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
VIP FAQ
What is VIP?
A neuropeptide found throughout the body that regulates blood flow, immune responses, and gut function. Studied for its role in chronic inflammatory conditions.
How does VIP work?
Acts on VPAC1 and VPAC2 receptors to dilate blood vessels, reduce inflammation, and regulate immune cell activity. In the gut, it controls secretion and motility.
Is VIP FDA approved?
No. VIP is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of VIP?
Reported half-life: ~1-2 minutes (rapid degradation).
How is VIP taken?
Intranasal spray or subcutaneous injection.
What side effects have been reported with VIP?
Reported in the sources: Diarrhea; Low blood pressure; Flushing; Rapid heart rate; Nasal congestion (intranasal use); Not widely available.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.